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Abstract: We report the first exocyclically metallated tetrapyridinoporphyrazine, [tetrakis-(trans-Pt(NH3)2Cl)-
tetra(3,4-pyrido)porphyrazine-zinc(II)](NO3)4 (4), synthesized in a multistep synthesis starting from 3,4-
pyridinedicarbonitrile (1). The synthetic procedure involved a platination reaction of the intermediate
tetra(3,4-pyrido)porphyrazine-zinc(II) (2), whereby the zinc(II) enhanced the solubility of the interme-
diate enabling the platination reaction. A similar approach to synthesize [tetrakis-(trans-Pt(NH3)2Cl)-
tetra(3,4-pyrido)porphyrazine](NO3)4 (5) failed due to the unsuitable solubility properties of the inter-
mediate tetra(3,4-pyrido)porphyrazine (3). The final product 4 and the intermediates were characterized,
the photochemical and photophysical properties were determined and the photocytotoxicities were inves-
tigated. We demonstrate that the platinated tetra-pyridinoporphyrazine 4 is a potential photosensitizer
for photodynamic therapy (PDT).
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We report the first exocyclically metallated tetrapyridinoporphyrazine, [tetrakis-(trans-Pt(NH3)2Cl)-tetra(3,4-
pyrido)porphyrazine-zinc(II)](NO3)4 (4), synthesized in a multistep synthesis starting from 3,4-pyridinedicar-
bonitrile (1). The synthetic procedure involved a platination reaction of the intermediate tetra(3,4-pyrido)
porphyrazine-zinc(II) (2), whereby the zinc(II) enhanced the solubility of the intermediate enabling the plati-
nation reaction. A similar approach to synthesize [tetrakis-(trans-Pt(NH3)2Cl)-tetra(3,4-pyrido)porphyrazine]
(NO3)4 (5) failed due to the unsuitable solubility properties of the intermediate tetra(3,4-pyrido)porphyrazine
(3). The final product 4 and the intermediates were characterized, the photochemical and photophysical
properties were determined and the photocytotoxicities were investigated. We demonstrate that the plati-
nated tetra-pyridinoporphyrazine 4 is a potential photosensitizer for photodynamic therapy (PDT).
Introduction
Photodynamic therapy (PDT) is a powerful therapeutic method
that utilizes a photosensitizer (PS), activated by light, to create
irreversible damage to the target tissue. PDT is widely used for
the treatment of a variety of premalignant and malignant
diseases.1–8 Besides being a valuable therapy in oncology, it is
applied as a treatment for localized infections, arterial dis-
eases and menorrhagia.9 The non-invasive nature of the treat-
ment together with the possibility for spatial and temporal
control, lack of cumulative toxicity and compatibility with
other treatment methods render PDT a very attractive thera-
peutic method for different types of cancer.2,9
PDT uses three main components; a PS, light of a specific
wavelength, and molecular oxygen in the tissue. The PS is intro-
duced into the organism where it accumulates in the tissue to
be treated. Further, the tissue-localized PS is excited from its
singlet ground state (S0) to the first excited state (S1) by light of
an adequate wavelength. After undergoing intersystem crossing
(ISC) from the S1 state, the energetically lower long-lived triplet
state (T1) of the PS can generate singlet oxygen (
1O2) and/or
other reactive oxygen species (ROS) while the PS relaxes to its
ground state.10 The generated ROS cause cellular damage
leading to the induction of cell death pathways.1,4
An ideal PS should exhibit a high chemical stability, low
dark toxicity, specificity to the target tissue as well as strong
electronic transition intensities between 650 nm and 850 nm,
referred to as the phototherapeutic window.11 Wavelengths
shorter than 650 nm display low tissue penetration and wave-
lengths longer than 850 nm are unable to induce the ROS-
creating PS pathways due to a lack of energy.9 Additionally, the
PS requires amphiphilic properties for the transportation
inside the body and cellular uptake.3,11 Current PDT limit-
ations are mostly attributed to PSs with absorption ranges
below 650 nm, resulting in a low tissue penetration of the
required light. Furthermore, in vivo accumulation of PSs due
to hydrophobic interactions results in a reduced cellular
uptake, lowering the efficiency of the treatment.12,13
Our group has previously reported the synthesis of exocycli-
cally tetraplatinated porphyrins.14 These compounds displayed
high phototoxic indexes (PI) against cancer cells, high singlet
oxygen quantum yields (ΦΔ) and a relevant cellular uptake.
14
However, porphyrins are known to exhibit twenty times
higher excitation coefficients in the blue region of the electro-
magnetic spectrum compared to the red region that lies in the
phototherapeutic window.8,11,15 To counter these PDT limit-
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ations of porphyrins, we propose the investigation of exo-
cyclically platinated tetra(pyrido)porphyrazine-based PSs.
Tetra(pyrido)porphyrazines and phthalocyanines are planar
aromatic macrocycles related to porphyrins and they display
an exceptional stability as well as a strong light absorption
around 670 nm, rendering them ideal for PDT in terms of
absorption properties.10
In order to counter their high aggregation tendency and
low solubility in aqueous media, we propose the exocyclic pla-
tination of tetra(pyrido)porphyrazines which induces a four-
fold positively charged character. The exocyclic platination
constitutes an alternative to the incorporation of hydrophilic
side groups.1 Cationic porphyrazines were previously reported
to exert an antibacterial effect and Zimcik and co-workers have
reported a twelvefold cationic tetra(pyrido)porphyrazine,
which displays an excellent dark to light toxicity ratio.16,17
Additionally, various pyridyl-substituted porphyrazines, which
were coordinated to palladium or platinum, are reported in
literature.18–21 However, to the best of our knowledge, no exo-
cyclically metallated tetra(pyrido)porphyrazines have been
reported so far.
Cisplatin is a known and extensively used chemotherapeu-
tic drug for the treatment of different cancer types including
ovarian and testicular cancer, whereby it induces cytotoxicity
by interfering with the DNA replication.14,22 Hence, in addition
to improving the PDT efficiency, the exocyclic platination of
tetra(pyrido)porphyrazines can render the compound a poten-
tial dual chemotherapeutic agent.14 Upon intravenous admin-
istration, cisplatin maintains a relatively stable neutral state
and forms cationic aqua complexes after cellular uptake due to
the lower intracellular chloride concentration. These positively
charged aqua complexes are unable to diffuse out of the cell
and bind to intracellular targets, most notably DNA, which
constitutes the main target.23 Therefore, the platination of PSs
could lead to a higher accumulation of the PS in cancerous
cells, resulting in a more efficient treatment. Current clinically
used platinum(II) drugs show side effects such as nephrotoxi-
city, ototoxicity, hepatotoxicity and cardiotoxicity. Moreover,
they are ineffective against certain cancer types due to intrinsic
or acquired resistance and these limitations call for new
improved platinum(II)-based chemotherapeutic agents.14,24
In our previous study, a porphyrin coupled to transplatin
showed the highest efficiency.14 Similarly, we reacted tetra(3,4-
pyrido)porphyrazines with four equivalents of transplatin,
resulting in the synthesis of [tetrakis-(trans-Pt(NH3)2Cl)-tetra-
(3,4-pyrido)porphyrazine-zinc(II)](NO3)4 (4). The compound
was characterized for its photochemical and photophysical
properties along with photocytotoxicity, DNA-binding constant
and intracellular localization in HeLa cells.
Results and discussion
Synthetic procedures
The syntheses of two tetra(3,4-pyrido)porphyrazines were exe-
cuted with 3,4-pyridinedicarbonitrile (1) as starting material,
resulting in tetra(3,4-pyrido)porphyrazine-zinc(II) (2)25–27 and
29H,31H-tetra(3,4-pyrido)porphyrazine (3).28 Both syntheses
were carried out according to literature reports, 2 as reported
by Dupouy et al.27 and 3 was synthesized according to the pro-
cedure reported by Ramirez et al.28 (Scheme 1).
Both tetra(3,4-pyrido)porphyrazines were synthesized in a
one-step synthesis, with DBU acting as base, catalyzing
the reactions. The main difference is the presence of
Zn(OAc)2·2H2O in the synthesis of 2, resulting in zinc(II) acting
as a template to facilitate the cyclotetramerization, which is
reflected in the in the high yield of 64%. During the formation
of 3 however, the lack of a metal ion lead to the formation of
various polymers. This resulted in a lower yield of 3 (28%)
compared to 2.
During the reaction, DBU deprotonates the alcohol which
then undertakes a nucleophilic attack on both the nitrile
groups, leading to two different intermediates. Hence, the
cyclotetramerization process leads to four different regio-
isomers of 2 and 3 (Fig. 1).
A reaction mechanism for the synthesis of phthalocyanines
from phthalonitriles was proposed by Tomoda et al.29 This
mechanism is equivalent to the synthesis of the tetra(3,4-
pyrido)porphyrazines reported in this work and is shown in
the ESI (Scheme S1†).
The presence of 2 and 3 was confirmed with IR and UV-Vis
spectroscopy as well as with (+)-ESI-MS and EA. Due to the low
solubility emerging from the large conjugated aromatic
systems of both tetra(3,4-pyrido)porphyrazines, 2 and 3 could
not be characterized by 1H-NMR and 13C-NMR spectroscopy.
This is a known limitation, as no NMR data were reported for
both 2 and 3 in literature so far.25–28 Characterization of 2 by
1H-NMR spectroscopy was reported by Szulbinski et al.,25
however, the corresponding data could not be found in the
publication.
In a second step, 2 and 3 were further used to synthesize the
two tetraplatinated compounds [tetrakis-(trans-Pt(NH3)2Cl)-
tetra(3,4-pyrido)porphyrazine-zinc(II)](NO3)4 (4) and [tetrakis-
(trans-Pt(NH3)2Cl)-tetra(3,4-pyrido)porphyrazine](NO3)4 (5).
Transplatin (6) was used for both reactions and was pre-acti-
vated with AgNO3 in DMF according to our previously reported
procedure.14 The formed [trans-Pt(NH3)2Cl]NO3 (7) was then
used for the tetraplatination of both tetra(3,4-pyrido)porphyra-
zines 2 and 3 (Scheme 2).
The platination approach with DMF as solvent was suc-
cessful in the case of 4 with a yield of 48%. The same platina-
tion approach failed in the case of 5 due to the low solubility
of 3. A further approach involving the use of an EtOH/DMF
mixture as solvent for the tetraplatination of 3 was similarly
unsuccessful. This indicates that in contrast to the tetra-
platinated 5,10,15,20-tetra(4-pyridyl)porphyrin compounds14
reported previously by our group, free base tetra(3,4-pyrido)-
porphyrazines exhibit a too low solubility to be used for plati-
nation reactions. Therefore, we propose the investigation of
exocyclically tetraplatinated metallo-tetra(pyrido)porphyra-
zines as potential PSs for PDT, as the presence of zinc(II)
enhanced the solubility and enabled a exocyclic platination
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of 2 compared to its free base analogue 3. The presence of 4
could be verified by IR, UV-Vis and 195Pt-NMR spectroscopy
as well as by (+)-ESI-MS and EA. The (+)-ESI-MS and
195Pt-NMR spectrum clearly indicate the formation of 4 as the
only platinated species. The 195Pt-NMR spectrum of 4 is
shown in the ESI (Fig. S1†).
Photochemical and photophysical properties
UV-Vis absorbance spectra of both the non-platinated tetra-
(3,4-pyrido)porphyrazines 2 and 3 as well as the tetraplatinated
compound 4 were measured in DMF. The comparison of the
absorbance spectra of 2 and 3 shows a similar absorption spec-
trum with two Q-bands at 663 and 674 nm in the case of 2 and
at 660 and 669 nm for 3, respectively. Also, the B-band is simi-
larly located at 380 nm in the case of 2 compared to 388 nm in
the case of 3. The absorbance spectrum of 4 shows that the
platination redshifts both the B-band and Q-bands, leading to
a B-band at 402 nm and two Q-bands at 680 and 692 nm in the
case of 4. The superimposed UV-Vis spectra of 2, 3 and 4 are
shown in Fig. 2.
Fluorescence emission spectra of 2, 3 and 4 were measured
in DMF. The superimposed normalized fluorescence emission
spectra are shown in Fig. 3. All three tetra(3,4-pyrido)porphyra-
zines were excited at 640 nm. The fluorescence emission
maxima of the three compounds are similar showing values
of 680 nm, 678 nm, 678 nm for 2, 3 and 4, respectively.
Compared to the UV-Vis absorption spectra, a red-shift is
observed in the case of the non-platinated tetra(3,4-pyrido)por-
phyrazines 2 and 3 and a small blue-shift was observed in the
case of 4.
Fluorescence emission lifetimes (τ) of 2, 3 and 4 were
measured as solutions in DMF with a 640 nm excitation wave-
length (Table 1). All three samples 2, 3 and 4 showed similar τ
around 3.00 ns (τ = 3.06 ns for 2, 2.99 ns for 3 and 2.80 ns
for 4). These values suggest that metallotetrapyridinoporphyra-
zines and free base tetrapyridinoporphyrazines do not differ in
fluorescence emission lifetimes and that the exocyclic platina-
Fig. 1 The four regioisomers formed during the syntheses of 2 and 3.
Scheme 1 Syntheses of tetra(3,4-pyrido)porphyrazine-zinc(II) (2) and 29H,31H-tetra(3,4-pyrido)porphyrazine (3).27,28
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Scheme 2 Synthetic procedure for the synthesis of [tetrakis-(trans-Pt(NH3)2Cl)-tetra(3,4-pyrido)porphyrazine-zinc(II)](NO3)4 (4) and the attempted
synthesis of [tetrakis-(trans-Pt(NH3)2Cl)-tetra(3,4-pyrido)porphyrazine](NO3)4 (5).
Fig. 2 UV-Vis absorbance spectra for 2 (green), 3 (blue) and 4 (red) (c =
6.0 × 10−5 M) measured in DMF.
Fig. 3 Normalized fluorescence emission spectra of 2 (green), 3 (blue)
and 4 (red) measured in DMF with a 640 nm excitation wavelength.
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tion does not shorten the lifetime of metallotetrapyridinopor-
phyrazines considerably.
Fluorescence quantum yields (Φf ) of 2, 3 and 4 were
measured in DMF with an excitation wavelength of 640 nm
(Table 1). The determined Φf values were 0.15 ± 0.02 for 2, 0.07
± 0.02 for 3 and 0.01 ± 0.02 for 4. A major difference was
observed for the Φf of 4 and its non-platinated precursor 2,
with 2 showing a Φf 14-times larger than 4. This difference is
attributed to the attached platinum nuclei in the case of 4.
Platinum(II) is reported to induce a heavy atom effect when
attached to the photochemical system of a PS leading to larger
percentages of ISC and hence, a smaller percentage of relax-
ation through fluorescence emission.30,31 This behavior is
desired in the case of PSs for PDT as a higher rate of ISC and
relaxation through ROS production renders a PS more
efficient. This underlines an additional beneficial property of
platinated PSs for PDT, next to the improved solubility in
aqueous media, improved cellular uptake and potential dual
chemotherapeutic effect.
The singlet oxygen quantum yields (ΦΔ) of 2, 3 and 4 were
determined based on the phosphorescence of the emerging
singlet oxygen (1O2) at 1270 nm (Table 1). All three com-
pounds were dissolved in DMF-d7 and excited at 630 nm, as
deuterated solvents were reported to increase the 1O2 lifetime,
leading to a more precise determination of the ΦΔ values.
32
ΦΔ values of 0.21 ± 0.02 and 0.06 ± 0.01 were obtained for 2
and 3, respectively, which is in line with the Φf results, as the
aggregation of 3 in DMF is higher compared to 2, leading to
smaller quantum yield values. The low ΦΔ prevents 3 from
being an efficient PS, meanwhile the ΦΔ of 2 justifies further
optimization through platination. Interestingly, no phosphor-
escence at 1270 nm from generated 1O2 was observed in the
case of compound 4. This indicates that the tetraplatination
has an effect on the type of ROS species produced by the PS,
as the non-platinated precursor 2 was able to produce 1O2 in
contrast to 4. To verify that 4 undergoes another mechanism
upon irradiation leading to the production of other ROS
species such as hydroxyl radicals that do not exhibit phos-
phorescent properties at 1270 nm, intracellular ROS pro-
duction experiments were performed with 4.
Photostability experiments of 2, 3 and 4 were measured in
DMF. The solutions used for the UV-Vis data were remeasured
after one week under light exclusion and for a second time
after an additional week in day light. In both measurements,
no significant decay was observed, indicating that 2, 3 and 4
are photostable in solution (Fig. S2†).
Photocytotoxicity experiments
In vitro photocytotoxicity assays were carried out to evaluate
the anti-cancer activity of 2 and 4 (Fig. 4). As the nucleus regu-
lates gene expression and controls replication during cell
cycle, (light-induced) DNA damage caused by the PS inhibits
the cell division in cancer cells, leading to one of the various
cell death pathways.1,4 IC50 values of 2 and 4 were determined
in the HeLa cell line in the dark as well as after irradiation
with light to investigate the photocytotoxicity of 2 and 4. The
IC50 values of 2 turned out to be relatively high (34 μM in the
dark and 28 μM after irradiation with light), resulting in a
phototoxic index (PI) of 0.8, which indicates that compound 2
lacks a significant photocytotoxicity. Conversely, 4 showed a
lower IC50 value not only after light irradiation but also in the
dark (12 μM in the dark and 1.6 μM after irradiation with
light), resulting in a PI of 7.5. These results show, that 4 acts
as a dual chemotherapeutic agent, as the dark toxicity IC50
value of 4 is almost three times lower compared to 2 due to the
DNA-binding ability of the attached platinum complexes, indu-
cing at the same time a photocytotoxicity that was not
observed in the case of compound 2. A comparison experiment
with the well-known chemotherapeutic drug cisplatin (CisPt)
showed that CisPt exhibits an even higher IC50 value (17.9 μM)
under light exclusion compared to 4, while not showing any
photocytotoxicity after irradiation with light as expected
(17.4 μM). These results underline the dual chemotherapeutic
effect of 4 and show that single digit micromolar concen-
trations of 4 are able to induce photocytotoxicity.
Table 1 Photochemical and photophysical parameters of 2, 3 and 4
measured in DMF respectively DMF-d7 in the case of ΦΔ values
Substance 2 3 4
B-Band (λab.) 380 nm 388 nm 402 nm
Q-Bands (λab.) 663/674 nm 660/669 nm 680/692 nm
Fluorescence
(λex. = 640 nm)
680 nm 678 nm 678 nm
τ [ns] (λex. = 640 nm) 3.06 2.99 2.80
Φf (λex. = 640 nm) 0.15 ± 0.02 0.07 ± 0.02 0.01 ± 0.02
ΦΔ 0.21 ± 0.02 0.06 ± 0.01 0
Fig. 4 Results of dose-dependent cell viability assays of 2 (a), 4 (b) and CisPt (c) in HeLa cells. Cells were incubated with either 2, 4 or CisPt for 4 h
and subsequently treated with red light for 20 min. Cell viability was determined using resazurin after 72 h.
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A comparison of the PI values of both tetrapyridinoporphyr-
azines 2 and 4 with other porphyrazines reported in literature
is shown in Table 2. The selection of compounds was based on
the usage of similar light intensities for the determination of
the PI values. The comparison shows that 2 is indeed not
applicable as a potential photosensitizer for PDT, as it lacks
photocytotoxicity. On the contrary compound 4 shows photo-
cytotoxicity, however the PI value is rather small compared to
other porphyrazines reported in literature.33–35 This is attribu-
ted to the low dark toxicity value of 4, as none of the compared
porphyrazines was designed to cause a dual chemotherapeutic
effect. Therefore, the PI value of 4 is not directly comparable
with the values reported for these porphyrazines.
The intracellular localization of 4 was investigated using
fluorescence microscopy (Fig. 5 and S3†). HeLa cells were
treated with 4 (50 μM, red), stained with Hoechst 33258 (blue,
showing the nucleus) and imaged using high resolution con-
focal laser scanning microscopy (CLSM). The results show that
4 is taken up by the cancer cells from the extracellular environ-
ment within 2 h. Compound 4 mainly accumulates in the
nucleus, suggesting that 4 interacts with DNA, leading to sub-
sequent DNA damage and resulting in photocytotoxicity.
Additionally, no staining of the cytoplasmic or nuclear mem-
branes by compound 4 was detected.
The DNA-binding ability of 4 was determined with an ethi-
dium bromide (EB) intercalator displacement assay (Fig. 6).
The competition of 4 with EB for intercalating sites on ctDNA
was investigated by fluorescence emission during an EB displa-
cement titration. The competitive binding of 4 was calculated
as the apparent binding constant Kapp using fluorescence
spectra of EB (2 μM) saturated with ctDNA (100 μM) in a 9 : 1
PBS/DMF solvent mixture similar to our previous publication14





In (E1), KEB is the binding constant for EB (KEB =
1.0 × 107 M−1), [EB] designates the concentration of EB (2 μM)
and [4] designates the concentration of 4 at 50% quenching of
the ctDNA bound EB fluorescence emission.
The fluorescence emission of the intercalated EB at 600 nm
(λex = 546 nm) was monitored with stepwise increase in con-
centration of 4, whereby the fluorescence emission intensity of
the intercalated EB spectrum decreased as a result of the com-
petitive intercalating of 4 in ctDNA. A quenching of 50% of the
ctDNA bound EB fluorescence emission was observed at a
photosensitizer concentration of 13.8 μM, resulting in a Kapp
of 1.4 × 106 M−1. This binding constant shows a weaker inter-
calation activity for ctDNA compared to EB while neglecting
the crosslinking activity of 4 that is not present in EB.
Further, we investigated whether the phototoxicity exhibited
by 4 could be attributed to increased intracellular ROS levels
(Fig. 7 and S4†). HeLa cells were treated with 12 μM of 4 and
subjected to irradiation by the same light as used for the
photocytotoxicity assays. The ROS levels were detected using
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) fol-
lowed by fluorescence-activated cell sorting (FACS) analysis.
The non-fluorescent H2DCF-DA is converted into fluorescent
2′,7′-dichlorohydrofluorescein (DCF) upon oxidation by intra-
cellular ROS produced by photoactivation of the PS.5,38 Cells
treated with 4, displayed significantly higher ROS levels after
light irradiation, compared to treatment with light irradiation
alone or 4 alone (Fig. 7 and S4†). The data demonstrates that
photoactivation of 4 increases the percentage of cells display-
ing an increased ROS level by more than 27-fold compared
with the treatment of 4 in the dark, leading to the observed
photocytotoxicity. The increased ROS levels following light
irradiation demonstrate, despite the lack of detection of 1O2 in
the ΦΔ measurements, that 4 produces ROS species other than
1O2 to induce photocytotoxicity.
Table 2 A comparison of phototoxic indices (PI) of porphyrazine compounds reported in literature
Cpd. Cell line Dark toxicity Light toxicity Light source PI Ref.
Pz-PB A431 >60 μM 20 μM LED, λ 615–635 nm, 10 J cm−2 >3 36
Zn10 HeLa 105 μM 0.26 μM Xe lamp, λ > 570 nm, 11 J cm−2 404 33
2 HeLa 34 μM 28 μM Halogen lamp, λ > 600 nm, 6.96 J cm−2 0.8 This work
4 HeLa 12 μM 1.6 μM Halogen lamp, λ > 600 nm, 6.96 J cm−2 7.5 This work
Pz1 HSC-3 >10 μM 0.13 μM LED, λ 690 nm, 3.6 J cm−2 >77 34
Pc 5 HSC-3 >10 μM 0.022 μM LED, λ 690 nm, 3.6 J cm−2 >455 35
Fig. 5 The intracellular localization of compound 4 in HeLa cells. Cells
were incubated with compound 4 for 2 h prior to imaging. Confocal
images of cells doubly stained with Hoechst 33258 (a), 4 (b), wide-field
(c) and merged images (d) are presented.
Photochemical & Photobiological Sciences Paper
This journal is © The Royal Society of Chemistry and Owner Societies 2019 Photochem. Photobiol. Sci., 2019, 18, 2792–2803 | 2797
n-Octanol/water distribution
The n-octanol/water system has been widely used as a measure
of lipophilicity/hydrophilicity in modelling biological par-
tition/distribution to evaluate the distribution of potential
drug candidates in vivo.39 The distribution of compounds 2
and 4 in an n-octanol/PBS (pH 7.4) system was determined
using the shake-flask method and quantified using
RP-UPLC-ESI-MS (Fig. S5†).40 The results showed that 2 is
strongly lipophilic, as the compound was not detected in the
PBS phase and showed complete accumulation in the
n-octanol phase. This is in line with the known aqueous solu-
bility-based limitations of similar compounds such as zinc
phthalocyanine.41 Conversely, the tetraplatinated compound 4
only accumulated in the aqueous phase while not being detect-
able in the n-octanol phase. This shows that the platination-
induced fourfold positively charged character enhances the
hydrophilicity, rendering the compound usable in aqueous
systems such as the human body. Additionally, the high hydro-
philicity of 4 is advantageous for fast renal clearance and to
overcome issues connected with prolonged photosensitivity
after treatment.13
Experimental
The chemicals used were obtained from Acros Organics,
Chempur, Fluorochem, Fluka and Sigma-Aldrich, solvents
used for analysis were of reaction grade (Emsure), the remain-
ing solvents were of technical grade (Honeywell). Reactions
were monitored for completion by analysing a small sample by
TLC. Thin layer chromatography (TLC): Merck TLC plates silica
gel 60 on aluminium with the indicated solvent system; the
spots were visualized by UV light (254 nm and 366 nm). UV-Vis
spectra: Specord® 250 PLUS spectrophotometer (Analytic Jena);
λmax in nm. Fluorescence emission spectra: FLS900 fluo-
rescence spectrometer (Edinburgh Instruments); λmax in nm.
Fluorescence emission lifetime measurements were carried
out on a FLS900 fluorescence spectrometer (Edinburgh
Instruments) using an EPL-Laser (picosecond pulsed diode
laser) for excitation and a cooled micro-channel plate
photomultiplier (MCP-PMT) for single photon counting.
Fluorescence quantum yields (Φf ) were determined on a
FLS900 fluorescence spectrometer (Edinburgh Instruments)
using a F-M01 Integrating Sphere Assembly (Edinburgh
Instruments) and the corresponding software (Edinburgh
Instruments). Samples were measured as solutions in 1 cm
quartz cells. IR spectra: SpectrumTwo FT-IR Spectrometer
(PerkinElmer) equipped with a Specac Golden Gate™ ATR
(attenuated total reflection) accessory; applied as neat
samples; 1/λ in cm−1. 195Pt-NMR spectra in the indicated
solvent mixture; Bruker AV-500 (107.5 MHz); δ in ppm rel. to
K2PtCl6 in D2O (δ 0). High-resolution electrospray mass spectra
(HR-ESI-MS) were recorded on a maXis QTOF-MS instrument
(Bruker). Samples were dissolved in an appropriate solvent at a
concentration of around 1 µmol mL−1 and analyzed via con-
tinuous flow injection (2 μL min−1). The mass spectrometer
Fig. 6 Observed change in the fluorescence emission spectrum and at 600 nm of ctDNA bound EB with increasing concentration of 4.
Fig. 7 Intracellular ROS levels in HeLa cells treated with 12 μM com-
pound 4 for 4 h, irradiated with red light for 20 min. The ROS signal is
indicated as DCF fluorescence, measured using the BL1 channel (exci-
tation 488 nm, emission 530 nm) on an Attune NxT Cytometer and is
plotted against side scatter (SSC). The results are an average of three
independent experiments and the error bars represent standard
deviation.
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was operated in the positive electrospray ionization mode at
4000 V capillary voltage, −500 V endplate offset, with a N2
nebulizer pressure of 0.8 bar and dry gas flow of 4 l min−1 at
180 °C. Mass spectra were acquired in the mass range from
m/z 50 to 2000 at 20 000 resolution (full width at half
maximum) and 1.0 Hz rate. The mass analyzer was calibrated
between m/z 118 and 2721 using an Agilent ESI-L low concen-
tration tuning mix solution (Agilent) at a resolution of 20 000
and a mass accuracy below 2 ppm. All solvent used were pur-
chased in best LC-MS qualities. Elemental analysis was per-
formed on a LECO Truespec CHNS(O)-microanalyser.
RP-UPLC-ESI-MS spectra of the compounds were measured on
an Acquity Waters UPLC system coupled to Bruker HCT™
(Bremen) for the MS measurements, equipped with a DAD
detector and an auto sampler using an Acquity UPLC BEH C18
analytical column (1.7 μm, 50 × 2.1 mm). The LC run (flow
rate: 0.6 mL min−1) was performed with a linear gradient of
solvent A (distilled H2O containing 0.1% v/v formic acid) and
solvent B (CH3CN (Sigma-Aldrich HPLC-grade)); t = 0–0.5 min,
5% B; t = 0.51–4 min, from 95% A (5% B) to 0% A (100% B); t =
4–5 min, 0% A, 100% B. UV-Vis detection was collected at
388 nm and 402 nm. Light irradiation experiments (except for
the singlet oxygen quantum yield (ΦΔ) determination) were
performed using a Reflecta Diamator AF 2006 IR Hobby Line
250 W projector with a 600 nm long pass filter (square of
60 mm and 1 mm thick, Fig. S6†).
Synthetic procedures
Synthesis of tetra(3,4-pyrido)porphyrazine-zinc(II) (2).25–27
A 100 mL two-necked round bottom flask, connected to a
reflux condenser, was charged with n-pentanol (7.5 mL),
Zn(OAc)2·2H2O (92.2 mg, 0.42 mmol) and 3,4-pyridinedicarbo-
nitrile (1, 200 mg, 1.55 mmol). The mixture was stirred under
a N2 atmosphere at 100 °C for 10 min, afterwards DBU
(0.23 ml, 1.55 mmol) was added dropwise and the mixture was
stirred at 160 °C for 18 h. After completion of the reaction, the
mixture was cooled to 23 °C and cyclohexane (40 mL) was
added, then the mixture was kept at 23 °C for 2 h. The formed
precipitate was filtered and washed with H2O (20 mL) and
hexane (20 mL) to afford a dark solid, which was further puri-
fied. The solid was dissolved in MeOH (20 mL) and stirred at
40 °C for 1 h before H2O (30 mL) was added dropwise at 23 °C
to precipitate the product, which was filtered and recovered
with MeOH (20 mL). Finally, 2 was obtained as a dark blue
solid (150 mg, 0.03 mmol, 64%) upon drying in vacuo.
Spectroscopic data of 2: IR (Golden-Gate, [cm−1]): 1663w
(CvN), 1598m (CvC), 1571m, 1483m, 1428w, 1389m, 1336w,
1246m, 1189w, 1156w, 1073s, 1013s, 946w, 885m, 832m, 785w,
751m, 739s, 656w. UV-Vis (DMF, [nm], (log(ε [M−1 cm−1]))):
λmax 388 (4.6), 603 (4.3), 663 (4.9), 674 (4.9). Fluorescence emis-
sion (DMF, [nm]): λmax 680 (λex 640). (+)-ESI-MS: 581 (100,
[M + H]+). Anal. calc. for C28H12N12Zn·H2O·MeOH (631.91): C
55.12, H 2.87, N 26.60; found: C 54.76, H 2.28, N 26.36.
Synthesis of 29H,31H-tetra(3,4-pyrido)porphyrazine (3).28
A 50 mL two-necked round bottom flask, connected to a reflux
condenser, was charged with n-octanol (16 mL) and 3,4-pyr-
idinedicarbonitrile (1, 300 mg, 2.33 mmol). The mixture was
stirred at 100 °C for 10 min, afterwards DBU (1.40 mL,
9.32 mmol) was added dropwise and the mixture was heated
to 185 °C for 40 min with stirring. The reaction mixture was
then stirred at 185 °C for 2 h. After completion of the reaction,
the mixture was cooled to 23 °C and the formed precipitate
was filtered to afford a dark solid, which was further purified.
The solid was dissolved in H2O (30 mL) and stirred at 55 °C for
1 h. Afterwards the mixture was cooled down to 23 °C and the
solvent was pipetted out before the solid was dried in vacuo.
This purification procedure was repeated with MeOH (70 mL),
acetone (70 mL) and cyclohexane (70 mL). Finally, 3 was
obtained as a dark violet solid (88 mg, 0.02 mmol, 28%) by
transferring of the solid with the aid of MeOH (20 mL) and
drying in vacuo.
Spectroscopic data of 3: IR (Golden-Gate, [cm−1]): 1599m
(CvC), 1498w, 1447w, 1412w, 1386w, 1323w, 1252w, 1237w,
1194w, 1156w, 1111m, 1077m, 1055w, 998s, 931w, 890w,
874m, 831m, 744s, 736s, 687m. UV-Vis (DMF, [nm], (log(ε
[M−1 cm−1]))): λmax 380 (4.5), 607 (4.3), 660 (4.7), 669
(4.7). Fluorescence emission (DMF, [nm]): λmax 678 (λex 640).
(+)-ESI-MS: 519 (100, [M + H]+). Anal. calc. for
C28H14N12·H2O·MeOH (568.54): C 61.26, H 3.55, N 29.56;
found: C 61.79, H 2.94, N 29.18.
Synthesis of [tetrakis-(trans-Pt(NH3)2Cl)-tetra(3,4-pyrido)por-
phyrazine-zinc(II)](NO3)4 (4). A 20 mL round bottom flask was
charged with DMF (2 mL), trans-Pt(NH3)2Cl2 (6, 45 mg,
0.15 mmol) and AgNO3 (26 mg, 0.15 mmol). The mixture was
stirred at 55 °C for 23 h under exclusion of light, afterwards
the mixture was centrifuged and the yellow solution was trans-
ferred into a 20 mL round bottom flask. A solution of tetra(3,4-
pyrido)porphyrazine-zinc(II) (2) (20 mg, 0.03 mmol) in DMF
(2 mL) was added and the mixture was stirred at 50 °C for 48 h
with exclusion of light. After completion of the reaction, the
mixture was cooled to 23 °C and MTBE (5 mL) was added. The
mixture was filtered after 15 min, yielding a dark green precipi-
tate. The precipitate was washed with MeOH, DCM, MTBE and
n-hexane. Finally, 4 was obtained as a dark green solid (31 mg,
0.02 mmol, 48%) by transferring the solid with the aid of
n-hexane (10 mL) and drying in vacuo.
Spectroscopic data of 4: IR (Golden-Gate, [cm−1]): 3096w,
1622m, 1489m, 1312s, 1157w, 1083s, 911s, 823m, 848m, 761s,
744s, 688m, 668m. UV-Vis (DMF, [nm], (log(ε [M−1 cm−1]))):
λmax 402 (4.6), 680 (5.0), 691 (5.0). Fluorescence emission
(DMF, [nm]): λmax 678 (λex 640).
195Pt-NMR (DMSO-d6 :
methanol-d4 = 9 : 1): −3136 (s, 4 × Pt, Fig. S1†). (+)-ESI-MS
(DMF): 881 (4, [M − 2NO3]
2+), 855 (3, [M + Cl − 3NO3]
2+),
567 (30, [M − 3NO3]
3+), 558 (60, [M + Cl − 4NO3]
3+), 410
(30, [M − 4NO3]
4+). Anal. calc. for C28H36Cl4N24O12Pt4Zn·0.5
n-hexane (1931.36): C 19.28, H 2.24, N 17.41; found: C 19.40,
H 2.36, N 17.36.
Singlet oxygen quantum yields. The singlet oxygen quantum
yields (ΦΔ) of 2, 3 and 4 were determined analogously to a
method reported by Bonnet and coworkers.42 The PSs were dis-
solved in DMF-d7 and the solutions were placed in a glass
cuvette (114F-10-40, 10 mm × 4 mm dimensions, Hellma
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Analytics). The concentrations were adjusted to an absorption
intensity of 0.13 ± 0.02 at 630 nm, with the cuvette oriented in
a way that the light path equals to 10 mm. The cuvettes con-
taining the samples were placed in a CUV-UV/VIS-TC-ABS
temperature-controlled Qpod sample compartment (Avantes)
and cooled to 20 °C; temperature control was performed with
the use of a TC-125 controller (Quantum Northwest) and
Q-Blue software. Emission spectroscopy was conducted in a
custom-built setup (Fig. S7†), that is based on the setup
described by Meijer et al.42 Excitation was performed using a
high-power-LED 630 nm light source (FC5-LED-WL, Prismatix).
The light source was connected with an optical fibre (1000 μm
core diameter, Avantes) to the cuvette holder over a SMA 905
fibre optic connector. The intensity of the light source was
measured to be 10.0 mW cm−2 at the position of the cuvette.
The excitation power was measured using a S310C thermal
sensor connected to a PM100USB power meter (Thorlabs). The
connection piece used to insert the SMA connector into the
cuvette holder was replaced by an in-house custom-built con-
nection piece that allows the fibre to be inserted at a distance
of 2.0 cm from the cuvette. The detector (AvaSpec-NIR256-
1.7TEC, Avantes) was set to 0 °C and connected to the cuvette
holder with an optical fibre (600 μm diameter, Avantes).
Emission spectra were collected at a 90° angle with respect to
the excitation beam from 1100 to 1400 nm after three measure-
ment runs; every measurement run consisted of five averaged
measurements each lasting 9 s. All spectra were recorded
using AvaSoft 8.9 software from Avantes and further processed
using Microsoft Office Excel and Origin 2018 software.
The singlet oxygen quantum yields were calculated by com-
parison with a known literature standard (zinc phthalocyanine
(ZnPc): ΦΔ = 0.56 in DMF),









In (E2), the subscript × designates the corresponding photo-
sensitizer and std the standard (ZnPc). ΦΔ is the singlet oxygen
quantum yield. I630 is the rate of light absorption calculated as
overlap of the absorption spectrum of either PS or standard
and the emission spectrum of the LED light source at 630 nm.
E is the integrated emission peak of singlet oxygen at around
1270 nm. For these emission spectra, the integrated values
were obtained by applying a manual background correction in
Origin (Fig. S8†).
Cell culture. Human cervical carcinoma cells (HeLa) were
cultured in DMEM (Gibco) supplemented with 5% fetal calf
serum (Gibco), 100 U mL−1 penicillin, 100 μg mL−1 streptomy-
cin. The cells were grown at 37 °C and in 5% CO2 humidified
atmosphere.
Photocytotoxicity assays. The PS toxicity under light and
dark conditions was evaluated for a HeLa cell line, using a
resazurin-based fluorometric cell viability assay. Stock solu-
tions of the PS (3 mg mL−1) were prepared in DMF and stored
in the dark. The respective stock solutions were further diluted
with the complete medium to desired working concentrations.
For a typical experiment, 100 μL aliquots of cells in growth
medium were seeded in 96-well plates (density of 4 × 103 cells
per well) and incubated at 37 °C and 5% CO2. After 24 h of
incubation, cells were treated with different concentrations
(32 nM–100 μM, 200 μL final well volume) of the test com-
pounds and incubated for 4 h under light exclusion. For light
irradiation experiments, cells were treated for 4 h with com-
pounds, and the medium was replaced by fresh medium. Each
sample was placed 3 cm away from the red cut-off filter from
the projector. Cells were exposed to light (white light projector
with 600 nm filter) for 20 min (light intensity: 5.8 mW cm−2
for 20 min, light dose: 6.96 J cm−2), followed by additional
incubation for 20 h. Thereafter, for all experiments, the
medium was removed, 100 μL of freshly prepared resazurin
containing complete medium (0.2 mg mL−1 final concen-
tration) was added, and cells were incubated at 37 °C for 4 h.
Fluorescence of the resorufin product (λex = 540 nm) was quan-
tified at 590 nm using a SpectraMax M5 microplate Reader.
The reported cytotoxicity is an average of at least two indepen-
dent experiments, with triplicate determinations for each drug
concentration and the error bars demarcate the standard devi-
ation (S.D.). Final DMF concentration in the wells was less
than 0.5% (v/v) and control experiments with the same
amount of DMF in culture medium showed no cytotoxic effect
(results not shown).
Localization studies. HeLa cells were seeded in Ibidi μ-Slide
8-well glass bottom dishes and allowed to reach ≈70% con-
fluency. The medium was replaced with new medium and
freshly prepared solutions of drugs with a final concentration
of 50 μM were added. After 2 h incubation with compounds,
the cells were washed three times with PBS (0.5 mL) and
stored in fresh media containing 10% FBS for live-cell
imaging. Prior to imaging, the cells were incubated for 5 min
with 1.5 μM Hoechst 33258 (final concentrations). The fluo-
rescence of 4 was visualized with excitation from a 633 nm
HeNe laser and the red emission was collected using a 650 nm
long pass filter.
Detection of intracellular ROS levels. 2 × 105 HeLa cells
in 2 mL DMEM supplemented with 5% FBS were seeded
on 60 mm dishes. The following day, cells were treated
with 12 μM compound 4 for 4 hours. Following the incu-
bation, cells were washed with PBS and the medium was sub-
sequently replaced with 2 mL DMEM. Cells were irradiated
for 20 min with red light, as described for the photocyto-
toxicity assays. After irradiation, H2DCF-DA was added to
the samples to a final concentration of 50 μM and incubated
for 30 minutes at 37 °C. Cells were washed twice with
PBS and collected by trypsinisation. Cells were suspended in
1 mL PBS containing 1% FBS. Samples were analysed on an
Attune NxT Cytometer (Thermo Fisher Scientific) using BL1
channel (excitation 488 nm, emission 515 nm) to measure
DCF fluorescence. Results are expressed as mean percentage
of ROS levels over cell population, obtained from three inde-
pendent experiments with a minimum of 100 000 cells ana-
lysed per condition. The error bars represent standard devi-
ation (S.D).
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Determination of the n-octanol/water distribution. Stock
solutions (10 mM) of compounds 2 and 4 were prepared in
DMSO and diluted with a PBS (pH 7.4)/n-octanol system (1 : 1)
to reach a final compound concentration of 2.5 mM in a
volume of 1 mL. The mixtures were subsequently vortexed
before equilibration at 23 °C during 24 h. Then, the phases
were separated and diluted equally (PBS phase in H2O,
n-octanol phase in MeOH) to reach UPLC-suitable concen-
trations. The relative concentration of each compound in the
n-octanol and PBS phase was determined through the area
under curve in the analytical UPLC spectra.
Conclusion
The first exocyclically metallated tetrapyridinoporphyrazine 4
was synthesized, characterized and its photochemical and
photophysical properties as well as its phototoxicity against a
human cancer HeLa cell line were determined. A comparison
of the IC50 values of 4 and its nonplatinated precursor 2 shows
a clear improved effectivity of the substance emerging through
the exocyclic platination. Besides the additional heavy atom
effect emerging through the platinum species coupled to the
photochemical system, the platinum complexes help to
increase the solubility of tetrapyridinoporphyrazine PS in
aqueous media, induce a dual chemotherapeutic effect and
potentially increase the cellular uptake. We therefore propose
the further investigation of platinum(II)-coupled PS for PDT.
Conflicts of interest
There are no conflicts of interest to declare.
Acknowledgements
We thank the University of Zürich and the Swiss National
Science Foundation (205321_159976) for financial support.
WW is supported by a Swiss Government Excellence
Scholarship and the Novartis Foundation for Medical-
Biological Research. SF is supported by the Czech Science
Foundation grant 17-02080S. We thank Mathias Mosberger for
the help with the fluorescence lifetime measurements,
Dr Thomas Fox for recording the 195Pt-NMR spectrum and
Dr Michael S. Meijer as well as Prof. Sylvestre Bonnet for many
helpful discussions concerning singlet oxygen quantum yield
determination. Imaging was performed with equipment main-
tained by the Center for Microscopy and Image Analysis,
University of Zurich.
References
1 L. M. Moreira, F. V. dos Santos, J. P. Lyon, M. Maftoum-
Costa, C. Pacheco-Soares and N. S. da Silva, Photodynamic
therapy: Porphyrins and phthalocyanines as Photosensitizers,
Aust. J. Chem., 2008, 61, 741–754.
2 I. Yoon, J. Z. Li and Y. K. Shim, Advance in photosensitizers
and light delivery for photodynamic therapy, Clin. Endosc.,
2013, 46, 7–23.
3 Z. Jiang, J. Shao, T. Yang, J. Wang and L. Jia,
Pharmaceutical development, composition and quantitat-
ive analysis of phthalocyanine as the photosensitizer for
cancer photodynamic therapy, J. Pharm. Biomed. Anal.,
2014, 87, 98–104.
4 Y. Li, J. Wang, X. Zhang, W. Guo, F. Li, M. Yu, X. Kong,
W. Wu and Z. Hong, Highly water-soluble and tumor-tar-
geted photosensitizers for photodynamic therapy, Org.
Biomol. Chem., 2015, 13, 7681–7694.
5 P. M. Antoni, A. Naik, I. Albert, R. Rubbiani, S. Gupta,
P. Ruiz-Sanchez, P. Munikorn, J. M. Mateos, V. Luginbuehl,
P. Thamyongkit, U. Ziegler, G. Gasser, G. Jeschke and
B. Spingler, (Metallo)porphyrins as Potent Phototoxic Anti-
Cancer Agents after Irradiation with Red Light, Chem. –
Eur. J., 2015, 21, 1179–1183.
6 J. M. Dabrowski, B. Pucelik, A. Regiel-Futyra, M. Brindell,
O. Mazuryk, A. Kyziol, G. Stochel, W. Macyk and
L. G. Arnaut, Engineering of relevant photodynamic pro-
cesses through structural modifications of metallotetrapyr-
rolic photosensitizers, Coord. Chem. Rev., 2016, 325, 67–
101.
7 D. van Straten, V. Mashayekhi, H. S. de Bruijn, S. Oliveira
and D. J. Robinson, Oncologic Photodynamic Therapy:
Basic Principles, Current Clinical Status and Future
Directions, Cancers, 2017, 9, 19.
8 J. Zhang, C. Jiang, J. P. Figueiró Longo, R. B. Azevedo,
H. Zhang and L. A. Muehlmann, An updated overview on
the development of new photosensitizers for anticancer
photodynamic therapy, Acta Pharm. Sin. B, 2018, 8, 137–
146.
9 S. G. Bown, Photodynamic therapy for photochemists,
Philos. Trans. R. Soc., A, 2013, 371, 20120371.
10 K. Ishii, Functional singlet oxygen generators based on
phthalocyanines, Coord. Chem. Rev., 2012, 256, 1556–1568.
11 H. Abrahamse and M. R. Hamblin, New photosensitizers
for photodynamic therapy, Biochem. J., 2016, 473, 347–364.
12 J.-Y. Liu, X.-J. Jiang, W.-P. Fong and D. K. P. Ng, Highly
photocytotoxic 1,4-dipegylated zinc(II) phthalocyanines.
Effects of the chain length on the in vitro photodynamic
activities, Org. Biomol. Chem., 2008, 6, 4560–4566.
13 D. E. J. G. J. Dolmans, D. Fukumura and R. K. Jain,
Photodynamic therapy for cancer, Nat. Rev. Cancer, 2003, 3,
380–387.
14 A. Naik, R. Rubbiani, G. Gasser and B. Spingler, Visible-
Light-Induced Annihilation of Tumor Cells with Platinum–
Porphyrin Conjugates, Angew. Chem., Int. Ed., 2014, 53,
6938–6941.
15 A. Oniszczuk, K. A. Wojtunik-Kuleszaa, T. Oniszczuk and
K. Kasprzak, The potential of photodynamic therapy (PDT)-
Experimental investigations and clinical use, Biomed.
Pharmacother., 2016, 83, 912–929.
Photochemical & Photobiological Sciences Paper
This journal is © The Royal Society of Chemistry and Owner Societies 2019 Photochem. Photobiol. Sci., 2019, 18, 2792–2803 | 2801
16 L. Hassani, F. Hakimian, E. Safaei and Z. Fazeli,
Antibacterial effect of cationic porphyrazines and anionic
phthalocyanine and their interaction with plasmid DNA,
J. Mol. Struct., 2013, 1052, 221–227.
17 M. Machacek, J. Demuth, P. Cermak, M. Vavreckova,
L. Hruba, A. Jedlickova, P. Kubat, T. Simunek, V. Novakova
and P. Zimcik, Tetra(3,4-pyrido)porphyrazines Caught in
the Cationic Cage: Toward Nanomolar Active
Photosensitizers, J. Med. Chem., 2016, 59, 9443–9456.
18 M. P. Donzello, E. Viola, X. Cai, L. Mannina, C. Ercolani
and K. M. Kadish, Tetra-2,3-pyrazinoporphyrazines with
Externally Appended Pyridine Rings. 8. Central (ZnII, CuII,
MgII(H2O), Cd
II) and Exocyclic (PdII) Metal Ion Binding
in Heteropentametallic Complexes from Tetrakis-2,3-[5,6-
di(2-pyridyl)pyrazino]porphyrazine, Inorg. Chem., 2010, 49,
2447–2456.
19 I. Manet, F. Manoli, M. P. Donzello, E. Viola, A. Masi,
G. Andreano, G. Ricciardi, A. Rosa, L. Cellai, C. Ercolani
and S. Monti, Pyrazinoporphyrazines with Externally
Appended Pyridine Rings. 13. Structure, UV-Visible
Spectral Features, and Noncovalent Interaction with DNA
of a Positively Charged Binuclear (ZnII/PtII) Macrocycle with
Multimodal Anticancer Potentialities, Inorg. Chem., 2013,
52, 321–328.
20 M. P. Donzello, D. Vittori, D. Futur, Z. Fu, C. Ercolani and
K. M. Kadish, Tetra-2,3-pyrazinoporphyrazines with exter-
nally appended pyridine rings. 14. UV-visible spectral and
electrochemical behavior of homo/heterobinuclear neutral
and hexacationic macrocycles, J. Porphyrins Phthalocyanines,
2013, 17, 896–904.
21 M. P. Donzello, F. Gigante, F. Sciscione, E. Viola and
K. M. Kadish, Tetra-2,3-pyrazinoporphyrazines with
externally appended pyridine rings. 18. Physicochemical
properties and photochemical behavior of new
uncharged water soluble low-symmetry macrocycles
[{Pd(OAc)2}3(PtCl2)LM] (M = Mg
II(H2O), Zn
II, PdII),
J. Porphyrins Phthalocyanines, 2017, 21, 334–344.
22 A.-M. Florea and D. Büsselberg, Cisplatin as an Anti-Tumor
Drug: Cellular Mechanisms of Activity, Drug Resistance
and Induced Side Effects, Cancers, 2011, 3, 1351–1371.
23 Y. Jung and S. J. Lippard, Direct cellular responses to
platinum-induced DNA damage, Chem. Rev., 2007, 107,
1387–1407.
24 O. Vrana, V. Novohradsky, Z. Medrikova, J. Burdikova,
O. Stuchlikova, J. Kasparkova and V. Brabec, Internalization
of Ineffective Platinum Complex in Nanocapsules Renders It
Cytotoxic, Chem. – Eur. J., 2016, 22, 2728–2735.
25 W. S. Szulbinski and J. R. Kincaid, Synthesis and spectro-
scopic characterization of zinc tetra(3,4-pyridine)porphyra-
zine entrapped within the supercages of Y-zeolite, Inorg.
Chem., 1998, 37, 5014–5020.
26 C. Martí, S. Nonell, M. Nicolau and T. Torres,
Photophysical properties of neutral and cationic tetrapyri-
dinoporphyrazines, Photochem. Photobiol., 2000, 71, 53–59.
27 E. A. Dupouy, D. Lazzeri and E. N. Durantini,
Photodynamic activity of cationic and non-charged Zn(II)
tetrapyridinoporphyrazine derivatives: biological con-
sequences in human erythrocytes and Escherichia coli,
Photochem. Photobiol. Sci., 2004, 3, 992–998.
28 C. Ramirez, C. Antonacci, J. Ferreira and R. D. Sheardy, The
facile synthesis and characterization of novel cationic
metallated and nonmetallated tetrapyridino porphyrazines
having different metal centers, Synth. Commun., 2004, 34,
3373–3379.
29 H. Tomoda, S. Saito, S. Ogawa and S. Shiraishi, Synthesis
of Phthalocyanines from Phthalonitrile with Organic
Strong Bases, Chem. Lett., 1980, 9, 1277–1280.
30 M. Obata, S. Hirohara, R. Tanaka, I. Kinoshita, K. Ohkubo,
S. Fukuzumi, M. Tanihara and S. Yano, In Vitro Heavy-
Atom Effect of Palladium(II) and Platinum(II) Complexes of
Pyrrolidine-Fused Chlorin in Photodynamic Therapy,
J. Med. Chem., 2009, 52, 2747–2753.
31 S. Fukuzumi, K. Ohkubo, X. Zheng, Y. Chen, R. K. Pandey,
R. Zhan and K. M. Kadish, Metal Bacteriochlorins Which
Act as Dual Singlet Oxygen and Superoxide Generators,
J. Phys. Chem. B, 2008, 112, 2738–2746.
32 M. Bregnhøj, M. Westberg, F. Jensen and P. R. Ogilby,
Solvent-dependent singlet oxygen lifetimes: temperature
effects implicate tunneling and charge-transfer inter-
actions, Phys. Chem. Chem. Phys., 2016, 18, 22946–22961.
33 L. Vachova, M. Machacek, R. Kucera, J. Demuth, P. Cermak,
K. Kopecky, M. Miletin, A. Jedlickova, T. Simunek,
V. Novakova and P. Zimcik, Heteroatom-substituted tetra
(3,4-pyrido)porphyrazines: a stride toward near-infrared-
absorbing macrocycles, Org. Biomol. Chem., 2015, 13, 5608–
5612.
34 J. Piskorz, K. Konopka, N. Düzgünes, Z. Gdaniec,
J. Mielcarek and T. Goslinski, Diazepinoporphyrazines
Containing Peripheral Styryl Substituents and Their
Promising Nanomolar Photodynamic Activity against Oral
Cancer Cells in Liposomal Formulations, ChemMedChem,
2014, 9, 1775–1782.
35 P. Skupin-Mrugalska, W. Szczolko, P. Gierlich, K. Konopka,
T. Goslinski, J. Mielcarek and N. Düzgünes,
Physicochemical properties of liposome-incorporated
2-(morpholin-4-yl)ethoxy phthalocyanines and their photo-
dynamic activity against oral cancer cells, J. Photochem.
Photobiol., A, 2018, 353, 445–457.
36 N. Y. Shilyagina, N. N. Peskova, S. A. Lermontova,
A. A. Brilkina, V. A. Vodeneev, A. V. Yakimansky,
L. G. Klapshina and I. V. Balalaeva, Effective delivery of por-
phyrazine photosensitizers to cancer cells by polymer
brush nanocontainers, J. Biophotonics, 2017, 10, 1189–1197.
37 D. L. Boger, B. E. Fink, S. R. Brunette, W. C. Tse and
M. P. Hedrick, A simple, high-resolution method for estab-
lishing DNA binding affinity and sequence selectivity,
J. Am. Chem. Soc., 2001, 123, 5878–5891.
38 R. P. Rastogi, S. P. Singh, D.-P. Häder and R. P. Sinha,
Detection of reactive oxygen species (ROS) by the oxidant-
sensing probe 2′,7′-dichlorodihydrofluorescein diacetate
in the cyanobacterium Anabaena variabilis PCC 7937,
Biochem. Biophys. Res. Commun., 2010, 397, 603–607.
Paper Photochemical & Photobiological Sciences
2802 | Photochem. Photobiol. Sci., 2019, 18, 2792–2803 This journal is © The Royal Society of Chemistry and Owner Societies 2019
39 S. S. Bharate, V. Kumar and R. A. Vishwakarma, Determining
Partition Coefficient (Log P), Distribution Coefficient (Log D)
and Ionization Constant (pKa) in Early Drug Discovery,
Comb. Chem. High Throughput Screening, 2016, 19, 461–469.
40 V. Pierroz, T. Joshi, A. Leonidova, C. Mari, J. Schur,
I. Ott, L. Spiccia, S. Ferrari and G. Gasser, Molecular
and Cellular Characterization of the Biological Effects of
Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimi-
dine-4-carboxylic Acid, J. Am. Chem. Soc., 2012, 134, 20376–
20387.
41 H. K. Moon, M. Son, J. E. Park, S. M. Yoon, S. H. Lee and
H. C. Choi, Significant increase in the water dispersibility
of zinc phthalocyanine nanowires and applications in
cancer phototherapy, NPG Asia Mater., 2012, 4, e12.
42 M. S. Meijer, V. S. Talens, M. F. Hilbers, R. E. Kieltyka,
A. M. Brouwer, M. M. Natile and S. Bonnet, NIR-Light-
Driven Generation of Reactive Oxygen Species Using Ru(II)-
Decorated Lipid-Encapsulated Upconverting Nanoparticles,
Langmuir, 2019, 35, 12079–12090.
43 U. Michelsen, H. Kliesch, G. Schnurpfeil, A. K. Sobbi and
D. Wöhrle, Unsymmetrically substituted benzonaphthopor-
phyrazines: A new class of cationic photosensitizers for the
photodynamic therapy of cancer, Photochem. Photobiol.,
1996, 64, 694–701.
Photochemical & Photobiological Sciences Paper
This journal is © The Royal Society of Chemistry and Owner Societies 2019 Photochem. Photobiol. Sci., 2019, 18, 2792–2803 | 2803
S1 
Supporting Information for  
Exocyclically Metallated Tetrapyridinoporphyrazine as a Potential 























 Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, 
Switzerland. E-mail: spingler@chem.uzh.ch; Web: 
http://www.chem.uzh.ch/en/research/spingler.html; Fax: +41 44 635 68 02; Tel: +41 44 635 
46 56 
b
 Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057 
Zurich, Switzerland. E-mail: sferrari@imcr.uzh.ch; Web: 
http://www.imcr.uzh.ch/research/Ferrari.html; Fax: +41 44 635 34 84; Tel: +41 44 635 34 71 
c
 Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, 






Scheme S1. A reaction mechanism for the formation of 2 and 3 analogous to the one 











Figure S2. UV-Vis absorbance spectra of 2, 3 and 4 in DMF: Instantly measured (green), after 
one week under light exclusion (blue) and after one additional week in daylight (red). 
 
 
Figure S3. Control experiment for the intracellular localization of compound 4 in HeLa cells. 
Confocal images of cells without Hoechst 33258 staining and without compound 4 are 




In the table below, the average ROS levels for 3 independent experiments are given. 
 
Figure S4. A typical experiment showing the intracellular ROS levels in HeLa cells irradiated 
with red light for 20 min (left), treated with 12 M compound 4 for 4 h (middle) or treated 
with 12 M compound 4 for 4 h and irradiated with red light for 20 min (right). ROS signal is 
indicated as DCF fluorescence, measured using the BL1 channel (excitation 488 nm, emission 
530 nm) on an Attune NxT Cytometer and is plotted against side scatter (SSC). The median 
fluorescence intensity and the frequency of cells displaying ROS signal are shown. S.D 




Figure S5. RP-UPLC-ESI-MS spectra of a) n-octanol phase (2), b) PBS phase (2), c) n-octanol 
phase (4), d) PBS phase (4), showing that 2 only accumulates in the n-octanol phase and 4 
only in the PBS phase. 
 
 




Figure S7. Setup used for NIR emission spectroscopy. 1) LED light source, 2) Optical fibre 
(1000 m), 3) Custom-built connection piece, 4) SMA 905 fibre optic connector, 5) Cuvette in 
cuvette holder, 6) Blank, 7) Temperature-controlled Qpod cuvette holder, 8) Connection 
piece with QIL-UV AR-coated fused-silica imaging lens, 9) Optical fibre (600 m), 10) NIR 






Figure S8. Singlet oxygen phosphorescence emission intensity (a.u.) vs. wavelength (nm) 
plots of the measured solutions of substances 2 (top left), 3 (top right), and zinc 
phthalocyanine (ZnPc, bottom left). 
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